trial

Oxygen Therapy in Schizophrenia

NCTId NCT00525863
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Unknown
Enrollment 20 (estimated)
Sponsored by Beersheva Mental Health Center
Primary completion 2009-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Unknown
Enrollment
20 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2008-01
Primary completion
2009-12
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
oxygen

Sponsors

Beersheva Mental Health CenterLead Sponsor
National Alliance for Research on Schizophrenia and DepressionCollaborator

Investigators

1
Yuly Bersudsky, MD, PhDPrincipal Investigator

Sites

1 total
Beersheva, Israel

Linked catalysts

1
Oxygen Therapy in Schizophrenia — primary completion2009-12

Facts & assertions

4 sourced
Enrollment
20
Phase
PHASE3
Primary Completion Date
2009-12
Status
UNKNOWN
relationships
The graph out of here
drug
oxygen
drug
lead_sponsor
Beersheva Mental Health Center
company
collaborator
National Alliance for Research on Schizophrenia and Depression
company
indication
Schizophrenia
indication
Chronic Schizophrenia
indication
investigator
Yuly Bersudsky, MD, PhD
person